The MarketReader Minute
π IBB Down Amid Slower GDP; Regeneron, Biogen, Alnylam Impact Biotech Sector Performance | Biotech Sector Insights
(IBB) has experienced a decline of 1.2% since Wednesday. The U.S. private sector added 233,000 jobs in October, surpassing expectations and highlighting robust labor market conditions, while GDP growth slowed unexpectedly to an annualized rate of 2.8% for Q3.